PIPELINE OVERVIEW
|
PIPELINE
|
RECOTHROM®
OUTLICENSED PRODUCTS
|
CANDIDATE BACKGROUNDERS
Select Program:
Pipeline
IL-21
Interferon lambda-1
RECOTHROM
Outlicensed
Select Indication:
Antiviral
Autoimmunity/Inflammation
Hemostasis
Oncology
R & D
CLINICAL
POST-APPROVAL
Therapeutic Candidate
Target Indication
RECOTHROM
Surgical Hemostasis
Marketed
IL-21
Metastatic Melanoma
Phase 2
IL-21 & Nexavar
Renal Cell Carcinoma
Phase 2
IL-21 & Rituxan
Non-Hodgkin's Lymphoma
Phase 1
PEG-Interferon lambda
Hepatitis C
Phase 1
Back to top
copyright © 2003 - 2008 ZymoGenetics